APO Research
Talk to an analyst

APO RESEARCH · REPORT

Musculoskeletal System Disorder Drug

Compare research editions
View pricing & licenses

Selected research

Market Analysis & Forecast

Global Musculoskeletal System Disorder Drug Market Analysis and Forecast 2026-2032

29 December 2025205 pages

Choose your research edition.

Industry ResearchMusculoskeletal System Disorder Drug Industry Research Report 2026134 pages · $2,950 USDIndustry Growth & TrendsGlobal Musculoskeletal System Disorder Drug Industry Growth and Trends Forecast to 2032114 pages · $3,450 USDMarket StructureGlobal Musculoskeletal System Disorder Drug Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032190 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Musculoskeletal System Disorder Drug Market Outlook and Growth Opportunities 2026209 pages · $4,250 USDMarket Analysis & ForecastGlobal Musculoskeletal System Disorder Drug Market Analysis and Forecast 2026-2032205 pages · $4,950 USD

Market perspective

The global Musculoskeletal System Disorder Drug market is projected to grow from US$ million in 2026 to US$ million by 2032, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The North America market for Musculoskeletal System Disorder Drug is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Europe market for Musculoskeletal System Disorder Drug is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Read the full market overview

Asia-Pacific market for Musculoskeletal System Disorder Drug is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The China market for Musculoskeletal System Disorder Drug is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The major global companies of Musculoskeletal System Disorder Drug include Sanofi, Johnson & Johnson, Novartis, Eli Lilly, Pfizer, AbbVie, Torrent Pharmaceuticals, Nippon Shinyaku and Merck & Co, etc. In 2025, the world's top three vendors accounted for approximately % of the revenue.

Report Includes

This report presents an overview of global market for Musculoskeletal System Disorder Drug, market size. Analyses of the global market trends, with historic market revenue data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.

This report researches the key producers of Musculoskeletal System Disorder Drug, also provides the revenue of main regions and countries. Of the upcoming market potential for Musculoskeletal System Disorder Drug, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Musculoskeletal System Disorder Drug revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global Musculoskeletal System Disorder Drug market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2021 to 2032. Evaluation and forecast the market size for Musculoskeletal System Disorder Drug revenue, projected growth trends, production technology, application and end-user industry.

Musculoskeletal System Disorder Drug Segment by Company

Sanofi

Johnson & Johnson

Novartis

Eli Lilly

Pfizer

AbbVie

Torrent Pharmaceuticals

Nippon Shinyaku

Merck & Co

GSK

Eisai

Cadila Healthcare

Bayer

Astellas Pharma

Asahi Kasei

Amgen

Abbott

Musculoskeletal System Disorder Drug Segment by Type

Bone Disorder

Joint Disorder

Muscle Disorder

Other

Musculoskeletal System Disorder Drug Segment by Application

Hospital & Clinic

Retail Pharmacy

Other

Musculoskeletal System Disorder Drug Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.

2. To present the key players, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Musculoskeletal System Disorder Drug market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Musculoskeletal System Disorder Drug and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in market size), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Musculoskeletal System Disorder Drug.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Revenue of Musculoskeletal System Disorder Drug in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.

Chapter 4: Detailed analysis of Musculoskeletal System Disorder Drug company competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 5: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 6: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 7: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Musculoskeletal System Disorder Drug revenue, gross margin, and recent development, etc.

Chapter 8: North America by type, by application and by country, revenue for each segment.

Chapter 9: Europe by type, by application and by country, revenue for each segment.

Chapter 10: China type, by application, revenue for each segment.

Chapter 11: Asia (excluding China) type, by application and by region, revenue for each segment.

Chapter 12: South America, Middle East and Africa by type, by application and by country, revenue for each segment.

Chapter 13: The main concluding insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global Musculoskeletal System Disorder Drug Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Table 2. Bone Disorder Major Player Table 3. Joint Disorder Major Player Table 4. Muscle Disorder Major Player Table 5. Other Major Player Table 6. Global Musculoskeletal System Disorder Drug Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Table 7. Hospital & Clinic Major Player Table 8. Retail Pharmacy Major Player Table 9. Other Major Player Table 10. Musculoskeletal System Disorder Drug Industry Trends Table 11. Musculoskeletal System Disorder Drug Industry Drivers Table 12. Musculoskeletal System Disorder Drug Industry Opportunities and Challenges Table 13. Musculoskeletal System Disorder Drug Industry Restraints Table 14. Global Musculoskeletal System Disorder Drug Market Size Growth Rate (CAGR) by Region (US$ Million): 2021 VS 2025 VS 2032 Table 15. Global Musculoskeletal System Disorder Drug Market Size by Region (2021-2026) & (US$ Million) Table 16. Global Musculoskeletal System Disorder Drug Market Share by Region (2021-2026) Table 17. Global Musculoskeletal System Disorder Drug Market Size by Region (2027-2032) & (US$ Million) Table 18. Global Musculoskeletal System Disorder Drug Market Share by Region (2027-2032) Table 19. Global Musculoskeletal System Disorder Drug Revenue by Players (US$ Million) & (2021-2026) Table 20. Global Musculoskeletal System Disorder Drug Revenue Market Share by Players (2021-2026) Table 21. Global Musculoskeletal System Disorder Drug Key Players Ranking, 2024 VS 2025 VS 2026 Table 22. Global Musculoskeletal System Disorder Drug Key Players Headquarters & Area Served Table 23. Global Musculoskeletal System Disorder Drug Players, Product Type & Application Table 24. Global Musculoskeletal System Disorder Drug Players Establishment Date Table 25. Global Players Market Concentration Ratio (CR5 and HHI) Table 26. Global Musculoskeletal System Disorder Drug by Players Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 27. Global Musculoskeletal System Disorder Drug Revenue by Type 2021 VS 2025 VS 2032 (US$ Million) Table 28. Global Musculoskeletal System Disorder Drug Revenue by Type (2021-2026) & (US$ Million) Table 29. Global Musculoskeletal System Disorder Drug Revenue by Type (2027-2032) & (US$ Million) Table 30. Global Musculoskeletal System Disorder Drug Revenue Market Share by Type (2021-2026) Table 31. Global Musculoskeletal System Disorder Drug Revenue Market Share by Type (2027-2032) Table 32. Global Musculoskeletal System Disorder Drug Revenue by Application 2021 VS 2025 VS 2032 (US$ Million) Table 33. Global Musculoskeletal System Disorder Drug Revenue by Application (2021-2026) & (US$ Million) Table 34. Global Musculoskeletal System Disorder Drug Revenue by Application (2027-2032) & (US$ Million) Table 35. Global Musculoskeletal System Disorder Drug Revenue Market Share by Application (2021-2026) Table 36. Global Musculoskeletal System Disorder Drug Revenue Market Share by Application (2027-2032) Table 37. Sanofi Company Information Table 38. Sanofi Business Overview Table 39. Sanofi Musculoskeletal System Disorder Drug Revenue and Gross Margin (US$ Million) & (2021-2026) Table 40. Sanofi Musculoskeletal System Disorder Drug Product Portfolio Table 41. Sanofi Recent Development Table 42. Johnson & Johnson Company Information Table 43. Johnson & Johnson Business Overview Table 44. Johnson & Johnson Musculoskeletal System Disorder Drug Revenue and Gross Margin (US$ Million) & (2021-2026) Table 45. Johnson & Johnson Musculoskeletal System Disorder Drug Product Portfolio Table 46. Johnson & Johnson Recent Development Table 47. Novartis Company Information Table 48. Novartis Business Overview Table 49. Novartis Musculoskeletal System Disorder Drug Revenue and Gross Margin (US$ Million) & (2021-2026) Table 50. Novartis Musculoskeletal System Disorder Drug Product Portfolio Table 51. Novartis Recent Development Table 52. Eli Lilly Company Information Table 53. Eli Lilly Business Overview Table 54. Eli Lilly Musculoskeletal System Disorder Drug Revenue and Gross Margin (US$ Million) & (2021-2026) Table 55. Eli Lilly Musculoskeletal System Disorder Drug Product Portfolio Table 56. Eli Lilly Recent Development Table 57. Pfizer Company Information Table 58. Pfizer Business Overview Table 59. Pfizer Musculoskeletal System Disorder Drug Revenue and Gross Margin (US$ Million) & (2021-2026) Table 60. Pfizer Musculoskeletal System Disorder Drug Product Portfolio Table 61. Pfizer Recent Development Table 62. AbbVie Company Information Table 63. AbbVie Business Overview Table 64. AbbVie Musculoskeletal System Disorder Drug Revenue and Gross Margin (US$ Million) & (2021-2026) Table 65. AbbVie Musculoskeletal System Disorder Drug Product Portfolio Table 66. AbbVie Recent Development Table 67. Torrent Pharmaceuticals Company Information Table 68. Torrent Pharmaceuticals Business Overview Table 69. Torrent Pharmaceuticals Musculoskeletal System Disorder Drug Revenue and Gross Margin (US$ Million) & (2021-2026) Table 70. Torrent Pharmaceuticals Musculoskeletal System Disorder Drug Product Portfolio Table 71. Torrent Pharmaceuticals Recent Development Table 72. Nippon Shinyaku Company Information Table 73. Nippon Shinyaku Business Overview Table 74. Nippon Shinyaku Musculoskeletal System Disorder Drug Revenue and Gross Margin (US$ Million) & (2021-2026) Table 75. Nippon Shinyaku Musculoskeletal System Disorder Drug Product Portfolio Table 76. Nippon Shinyaku Recent Development Table 77. Merck & Co Company Information Table 78. Merck & Co Business Overview Table 79. Merck & Co Musculoskeletal System Disorder Drug Revenue and Gross Margin (US$ Million) & (2021-2026) Table 80. Merck & Co Musculoskeletal System Disorder Drug Product Portfolio Table 81. Merck & Co Recent Development Table 82. GSK Company Information Table 83. GSK Business Overview Table 84. GSK Musculoskeletal System Disorder Drug Revenue and Gross Margin (US$ Million) & (2021-2026) Table 85. GSK Musculoskeletal System Disorder Drug Product Portfolio Table 86. GSK Recent Development Table 87. Eisai Company Information Table 88. Eisai Business Overview Table 89. Eisai Musculoskeletal System Disorder Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 90. Eisai Musculoskeletal System Disorder Drug Product Portfolio Table 91. Eisai Recent Development Table 92. Cadila Healthcare Company Information Table 93. Cadila Healthcare Business Overview Table 94. Cadila Healthcare Musculoskeletal System Disorder Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 95. Cadila Healthcare Musculoskeletal System Disorder Drug Product Portfolio Table 96. Cadila Healthcare Recent Development Table 97. Bayer Company Information Table 98. Bayer Business Overview Table 99. Bayer Musculoskeletal System Disorder Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 100. Bayer Musculoskeletal System Disorder Drug Product Portfolio Table 101. Bayer Recent Development Table 102. Astellas Pharma Company Information Table 103. Astellas Pharma Business Overview Table 104. Astellas Pharma Musculoskeletal System Disorder Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 105. Astellas Pharma Musculoskeletal System Disorder Drug Product Portfolio Table 106. Astellas Pharma Recent Development Table 107. Asahi Kasei Company Information Table 108. Asahi Kasei Business Overview Table 109. Asahi Kasei Musculoskeletal System Disorder Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 110. Asahi Kasei Musculoskeletal System Disorder Drug Product Portfolio Table 111. Asahi Kasei Recent Development Table 112. Amgen Company Information Table 113. Amgen Business Overview Table 114. Amgen Musculoskeletal System Disorder Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 115. Amgen Musculoskeletal System Disorder Drug Product Portfolio Table 116. Amgen Recent Development Table 117. Abbott Company Information Table 118. Abbott Business Overview Table 119. Abbott Musculoskeletal System Disorder Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 120. Abbott Musculoskeletal System Disorder Drug Product Portfolio Table 121. Abbott Recent Development Table 122. North America Musculoskeletal System Disorder Drug Revenue by Type (2021-2026) & (US$ Million) Table 123. North America Musculoskeletal System Disorder Drug Revenue by Type (2027-2032) & (US$ Million) Table 124. North America Musculoskeletal System Disorder Drug Revenue by Application (2021-2026) & (US$ Million) Table 125. North America Musculoskeletal System Disorder Drug Revenue by Application (2027-2032) & (US$ Million) Table 126. North America Musculoskeletal System Disorder Drug Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 127. North America Musculoskeletal System Disorder Drug Revenue by Country (2021-2026) & (US$ Million) Table 128. North America Musculoskeletal System Disorder Drug Revenue by Country (US$ Million) & (2027-2032) Table 129. Europe Musculoskeletal System Disorder Drug Revenue by Type (2021-2026) & (US$ Million) Table 130. Europe Musculoskeletal System Disorder Drug Revenue by Type (2027-2032) & (US$ Million) Table 131. Europe Musculoskeletal System Disorder Drug Revenue by Application (2021-2026) & (US$ Million) Table 132. Europe Musculoskeletal System Disorder Drug Revenue by Application (2027-2032) & (US$ Million) Table 133. Europe Musculoskeletal System Disorder Drug Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 134. Europe Musculoskeletal System Disorder Drug Revenue by Country (2021-2026) & (US$ Million) Table 135. Europe Musculoskeletal System Disorder Drug Revenue by Country (US$ Million) & (2027-2032) Table 136. China Musculoskeletal System Disorder Drug Revenue by Type (2021-2026) & (US$ Million) Table 137. China Musculoskeletal System Disorder Drug Revenue by Type (2027-2032) & (US$ Million) Table 138. China Musculoskeletal System Disorder Drug Revenue by Application (2021-2026) & (US$ Million) Table 139. China Musculoskeletal System Disorder Drug Revenue by Application (2027-2032) & (US$ Million) Table 140. Asia Musculoskeletal System Disorder Drug Revenue by Type (2021-2026) & (US$ Million) Table 141. Asia Musculoskeletal System Disorder Drug Revenue by Type (2027-2032) & (US$ Million) Table 142. Asia Musculoskeletal System Disorder Drug Revenue by Application (2021-2026) & (US$ Million) Table 143. Asia Musculoskeletal System Disorder Drug Revenue by Application (2027-2032) & (US$ Million) Table 144. Asia Musculoskeletal System Disorder Drug Revenue by Region (2021 VS 2025 VS 2032) & (US$ Million) Table 145. Asia Musculoskeletal System Disorder Drug Revenue by Region (US$ Million) & (2021-2026) Table 146. Asia Musculoskeletal System Disorder Drug Revenue by Region (US$ Million) & (2027-2032) Table 147. SAMEA Musculoskeletal System Disorder Drug Revenue by Type (2021-2026) & (US$ Million) Table 148. SAMEA Musculoskeletal System Disorder Drug Revenue by Type (2027-2032) & (US$ Million) Table 149. SAMEA Musculoskeletal System Disorder Drug Revenue by Application (2021-2026) & (US$ Million) Table 150. SAMEA Musculoskeletal System Disorder Drug Revenue by Application (2027-2032) & (US$ Million) Table 151. SAMEA Musculoskeletal System Disorder Drug Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 152. SAMEA Musculoskeletal System Disorder Drug Revenue by Country (2021-2026) & (US$ Million) Table 153. SAMEA Musculoskeletal System Disorder Drug Revenue by Country (US$ Million) & (2027-2032) Table 154. Research Programs/Design for This Report Table 155. Authors List of This Report Table 156. Secondary Sources Table 157. Primary Sources List of Figures Figure 1. Musculoskeletal System Disorder Drug Image Figure 2. Global Musculoskeletal System Disorder Drug Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Musculoskeletal System Disorder Drug Market Size Share 2021 VS 2025 VS 2032 Figure 4. Bone Disorder Image Figure 5. Joint Disorder Image Figure 6. Muscle Disorder Image Figure 7. Other Image Figure 8. Global Musculoskeletal System Disorder Drug Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Figure 9. Global Musculoskeletal System Disorder Drug Market Size Share 2021 VS 2025 VS 2032 Figure 10. Hospital & Clinic Image Figure 11. Retail Pharmacy Image Figure 12. Other Image Figure 13. Global Musculoskeletal System Disorder Drug Market Size (US$ Million) & (2021-2032) Figure 14. Global Musculoskeletal System Disorder Drug Market Size, (US$ Million), 2021 VS 2025 VS 2032 Figure 15. Global Musculoskeletal System Disorder Drug Market Share by Region: 2021 VS 2025 VS 2032 Figure 16. Global Musculoskeletal System Disorder Drug Players Revenue Share Top 10 and Top 5 in 2025 Figure 17. Players Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 18. Global Musculoskeletal System Disorder Drug Revenue by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 19. Global Musculoskeletal System Disorder Drug Revenue Market Share 2021 VS 2025 VS 2032 Figure 20. Global Musculoskeletal System Disorder Drug Revenue Market Share by Type (2021-2032) Figure 21. Global Musculoskeletal System Disorder Drug Revenue by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 22. Global Musculoskeletal System Disorder Drug Revenue Market Share by Application (2021 VS 2025 VS 2032) Figure 23. Global Musculoskeletal System Disorder Drug Revenue Market Share by Application (2021-2032) Figure 24. North America Musculoskeletal System Disorder Drug Revenue YoY Growth (2021-2032) & (US$ Million) Figure 25. North America Musculoskeletal System Disorder Drug Revenue Share by Type (2021-2032) Figure 26. North America Musculoskeletal System Disorder Drug Revenue Share by Application (2021-2032) Figure 27. North America Musculoskeletal System Disorder Drug Revenue Share by Country (2021-2032) Figure 28. United States Musculoskeletal System Disorder Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 29. Canada Musculoskeletal System Disorder Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 30. Mexico Musculoskeletal System Disorder Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 31. Europe Musculoskeletal System Disorder Drug Revenue YoY Growth (2021-2032) & (US$ Million) Figure 32. Europe Musculoskeletal System Disorder Drug Revenue Share by Type (2021-2032) Figure 33. Europe Musculoskeletal System Disorder Drug Revenue Share by Application (2021-2032) Figure 34. Europe Musculoskeletal System Disorder Drug Revenue Share by Country (2021-2032) Figure 35. Germany Musculoskeletal System Disorder Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 36. France Musculoskeletal System Disorder Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 37. U.K. Musculoskeletal System Disorder Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 38. Italy Musculoskeletal System Disorder Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 39. Spain Musculoskeletal System Disorder Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 40. Russia Musculoskeletal System Disorder Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 41. Netherlands Musculoskeletal System Disorder Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 42. Nordic Countries Musculoskeletal System Disorder Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 43. China Musculoskeletal System Disorder Drug Revenue YoY Growth (2021-2032) & (US$ Million) Figure 44. China Musculoskeletal System Disorder Drug Revenue Share by Type (2021-2032) Figure 45. China Musculoskeletal System Disorder Drug Revenue Share by Application (2021-2032) Figure 46. Asia Musculoskeletal System Disorder Drug Revenue YoY Growth (2021-2032) & (US$ Million) Figure 47. Asia Musculoskeletal System Disorder Drug Revenue Share by Type (2021-2032) Figure 48. Asia Musculoskeletal System Disorder Drug Revenue Share by Application (2021-2032) Figure 49. Asia Musculoskeletal System Disorder Drug Revenue Share by Region (2021-2032) Figure 50. Japan Musculoskeletal System Disorder Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 51. South Korea Musculoskeletal System Disorder Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 52. India Musculoskeletal System Disorder Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 53. Australia Musculoskeletal System Disorder Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 54. Taiwan Musculoskeletal System Disorder Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 55. Southeast Asia Musculoskeletal System Disorder Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 56. SAMEA Musculoskeletal System Disorder Drug Revenue YoY Growth (2021-2032) & (US$ Million) Figure 57. SAMEA Musculoskeletal System Disorder Drug Revenue Share by Type (2021-2032) Figure 58. SAMEA Musculoskeletal System Disorder Drug Revenue Share by Application (2021-2032) Figure 59. SAMEA Musculoskeletal System Disorder Drug Revenue Share by Country (2021-2032) Figure 60. Brazil Musculoskeletal System Disorder Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 61. Argentina Musculoskeletal System Disorder Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 62. Chile Musculoskeletal System Disorder Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 63. Colombia Musculoskeletal System Disorder Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 64. Peru Musculoskeletal System Disorder Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 65. Saudi Arabia Musculoskeletal System Disorder Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 66. Israel Musculoskeletal System Disorder Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 67. UAE Musculoskeletal System Disorder Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 68. Turkey Musculoskeletal System Disorder Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 69. Iran Musculoskeletal System Disorder Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 70. Egypt Musculoskeletal System Disorder Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 71. Years Considered Figure 72. Research Process Figure 73. Key Executives Interviewed

Scope & coverage.

Types
  • Bone Disorder
  • Joint Disorder
  • Muscle Disorder
  • Other
Applications
  • Hospital & Clinic
  • Retail Pharmacy
  • Other
Companies covered
  • Sanofi
  • Johnson & Johnson
  • Novartis
  • Eli Lilly
  • Pfizer
  • AbbVie
  • Torrent Pharmaceuticals
  • Nippon Shinyaku
  • Merck & Co
  • GSK
  • Eisai
  • Cadila Healthcare
  • Bayer
  • Astellas Pharma
  • Asahi Kasei
  • Amgen
  • Abbott

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Musculoskeletal System Disorder Drug Market by Type
  3. 1.2.1 Global Musculoskeletal System Disorder Drug Market Size by Type, 2021 VS 2025 VS 2032
  4. 1.2.2 Bone Disorder
  5. 1.2.3 Joint Disorder
  6. 1.2.4 Muscle Disorder
  7. 1.2.5 Other
  8. 1.3 Musculoskeletal System Disorder Drug Market by Application
  9. 1.3.1 Global Musculoskeletal System Disorder Drug Market Size by Application, 2021 VS 2025 VS 2032
  10. 1.3.2 Hospital & Clinic
  11. 1.3.3 Retail Pharmacy
  12. 1.3.4 Other
  13. 1.4 Assumptions and Limitations
  14. 1.5 Study Goals and Objectives
2 Musculoskeletal System Disorder Drug Market Dynamics
  1. 2.1 Musculoskeletal System Disorder Drug Industry Trends
  2. 2.2 Musculoskeletal System Disorder Drug Industry Drivers
  3. 2.3 Musculoskeletal System Disorder Drug Industry Opportunities and Challenges
  4. 2.4 Musculoskeletal System Disorder Drug Industry Restraints
3 Global Growth Perspective
  1. 3.1 Global Musculoskeletal System Disorder Drug Market Perspective (2021-2032)
  2. 3.2 Global Musculoskeletal System Disorder Drug Growth Trends by Region
  3. 3.2.1 Global Musculoskeletal System Disorder Drug Market Size by Region: 2021 VS 2025 VS 2032
  4. 3.2.2 Global Musculoskeletal System Disorder Drug Market Size by Region (2021-2026)
  5. 3.2.3 Global Musculoskeletal System Disorder Drug Market Size by Region (2027-2032)
4 Competitive Landscape by Players
  1. 4.1 Global Musculoskeletal System Disorder Drug Revenue by Players
  2. 4.1.1 Global Musculoskeletal System Disorder Drug Revenue by Players (2021-2026)
  3. 4.1.2 Global Musculoskeletal System Disorder Drug Revenue Market Share by Players (2021-2026)
  4. 4.1.3 Global Musculoskeletal System Disorder Drug Players Revenue Share Top 10 and Top 5 in 2025
  5. 4.2 Global Musculoskeletal System Disorder Drug Key Players Ranking, 2024 VS 2025 VS 2026
  6. 4.3 Global Musculoskeletal System Disorder Drug Key Players Headquarters & Area Served
  7. 4.4 Global Musculoskeletal System Disorder Drug Players, Product Type & Application
  8. 4.5 Global Musculoskeletal System Disorder Drug Players Establishment Date
  9. 4.6 Market Competitive Analysis
  10. 4.6.1 Global Musculoskeletal System Disorder Drug Market CR5 and HHI
  11. 4.6.3 2025 Musculoskeletal System Disorder Drug Tier 1, Tier 2, and Tier 3
5 Musculoskeletal System Disorder Drug Market Size by Type
  1. 5.1 Global Musculoskeletal System Disorder Drug Revenue by Type (2021 VS 2025 VS 2032)
  2. 5.2 Global Musculoskeletal System Disorder Drug Revenue by Type (2021-2032)
  3. 5.3 Global Musculoskeletal System Disorder Drug Revenue Market Share by Type (2021-2032)
6 Musculoskeletal System Disorder Drug Market Size by Application
  1. 6.1 Global Musculoskeletal System Disorder Drug Revenue by Application (2021 VS 2025 VS 2032)
  2. 6.2 Global Musculoskeletal System Disorder Drug Revenue by Application (2021-2032)
  3. 6.3 Global Musculoskeletal System Disorder Drug Revenue Market Share by Application (2021-2032)
7 Company Profiles
  1. 7.1 Sanofi
  2. 7.1.1 Sanofi Company Information
  3. 7.1.2 Sanofi Business Overview
  4. 7.1.3 Sanofi Musculoskeletal System Disorder Drug Revenue and Gross Margin (2021-2026)
  5. 7.1.4 Sanofi Musculoskeletal System Disorder Drug Product Portfolio
  6. 7.1.5 Sanofi Recent Developments
  7. 7.2 Johnson & Johnson
  8. 7.2.1 Johnson & Johnson Company Information
  9. 7.2.2 Johnson & Johnson Business Overview
  10. 7.2.3 Johnson & Johnson Musculoskeletal System Disorder Drug Revenue and Gross Margin (2021-2026)
  11. 7.2.4 Johnson & Johnson Musculoskeletal System Disorder Drug Product Portfolio
  12. 7.2.5 Johnson & Johnson Recent Developments
  13. 7.3 Novartis
  14. 7.3.1 Novartis Company Information
  15. 7.3.2 Novartis Business Overview
  16. 7.3.3 Novartis Musculoskeletal System Disorder Drug Revenue and Gross Margin (2021-2026)
  17. 7.3.4 Novartis Musculoskeletal System Disorder Drug Product Portfolio
  18. 7.3.5 Novartis Recent Developments
  19. 7.4 Eli Lilly
  20. 7.4.1 Eli Lilly Company Information
  21. 7.4.2 Eli Lilly Business Overview
  22. 7.4.3 Eli Lilly Musculoskeletal System Disorder Drug Revenue and Gross Margin (2021-2026)
  23. 7.4.4 Eli Lilly Musculoskeletal System Disorder Drug Product Portfolio
  24. 7.4.5 Eli Lilly Recent Developments
  25. 7.5 Pfizer
  26. 7.5.1 Pfizer Company Information
  27. 7.5.2 Pfizer Business Overview
  28. 7.5.3 Pfizer Musculoskeletal System Disorder Drug Revenue and Gross Margin (2021-2026)
  29. 7.5.4 Pfizer Musculoskeletal System Disorder Drug Product Portfolio
  30. 7.5.5 Pfizer Recent Developments
  31. 7.6 AbbVie
  32. 7.6.1 AbbVie Company Information
  33. 7.6.2 AbbVie Business Overview
  34. 7.6.3 AbbVie Musculoskeletal System Disorder Drug Revenue and Gross Margin (2021-2026)
  35. 7.6.4 AbbVie Musculoskeletal System Disorder Drug Product Portfolio
  36. 7.6.5 AbbVie Recent Developments
  37. 7.7 Torrent Pharmaceuticals
  38. 7.7.1 Torrent Pharmaceuticals Company Information
  39. 7.7.2 Torrent Pharmaceuticals Business Overview
  40. 7.7.3 Torrent Pharmaceuticals Musculoskeletal System Disorder Drug Revenue and Gross Margin (2021-2026)
  41. 7.7.4 Torrent Pharmaceuticals Musculoskeletal System Disorder Drug Product Portfolio
  42. 7.7.5 Torrent Pharmaceuticals Recent Developments
  43. 7.8 Nippon Shinyaku
  44. 7.8.1 Nippon Shinyaku Company Information
  45. 7.8.2 Nippon Shinyaku Business Overview
  46. 7.8.3 Nippon Shinyaku Musculoskeletal System Disorder Drug Revenue and Gross Margin (2021-2026)
  47. 7.8.4 Nippon Shinyaku Musculoskeletal System Disorder Drug Product Portfolio
  48. 7.8.5 Nippon Shinyaku Recent Developments
  49. 7.9 Merck & Co
  50. 7.9.1 Merck & Co Company Information
  51. 7.9.2 Merck & Co Business Overview
  52. 7.9.3 Merck & Co Musculoskeletal System Disorder Drug Revenue and Gross Margin (2021-2026)
  53. 7.9.4 Merck & Co Musculoskeletal System Disorder Drug Product Portfolio
  54. 7.9.5 Merck & Co Recent Developments
  55. 7.10 GSK
  56. 7.10.1 GSK Company Information
  57. 7.10.2 GSK Business Overview
  58. 7.10.3 GSK Musculoskeletal System Disorder Drug Revenue and Gross Margin (2021-2026)
  59. 7.10.4 GSK Musculoskeletal System Disorder Drug Product Portfolio
  60. 7.10.5 GSK Recent Developments
  61. 7.11 Eisai
  62. 7.11.1 Eisai Company Information
  63. 7.11.2 Eisai Business Overview
  64. 7.11.3 Eisai Musculoskeletal System Disorder Drug Revenue and Gross Margin (2021-2026)
  65. 7.11.4 Eisai Musculoskeletal System Disorder Drug Product Portfolio
  66. 7.11.5 Eisai Recent Developments
  67. 7.12 Cadila Healthcare
  68. 7.12.1 Cadila Healthcare Company Information
  69. 7.12.2 Cadila Healthcare Business Overview
  70. 7.12.3 Cadila Healthcare Musculoskeletal System Disorder Drug Revenue and Gross Margin (2021-2026)
  71. 7.12.4 Cadila Healthcare Musculoskeletal System Disorder Drug Product Portfolio
  72. 7.12.5 Cadila Healthcare Recent Developments
  73. 7.13 Bayer
  74. 7.13.1 Bayer Company Information
  75. 7.13.2 Bayer Business Overview
  76. 7.13.3 Bayer Musculoskeletal System Disorder Drug Revenue and Gross Margin (2021-2026)
  77. 7.13.4 Bayer Musculoskeletal System Disorder Drug Product Portfolio
  78. 7.13.5 Bayer Recent Developments
  79. 7.14 Astellas Pharma
  80. 7.14.1 Astellas Pharma Company Information
  81. 7.14.2 Astellas Pharma Business Overview
  82. 7.14.3 Astellas Pharma Musculoskeletal System Disorder Drug Revenue and Gross Margin (2021-2026)
  83. 7.14.4 Astellas Pharma Musculoskeletal System Disorder Drug Product Portfolio
  84. 7.14.5 Astellas Pharma Recent Developments
  85. 7.15 Asahi Kasei
  86. 7.15.1 Asahi Kasei Company Information
  87. 7.15.2 Asahi Kasei Business Overview
  88. 7.15.3 Asahi Kasei Musculoskeletal System Disorder Drug Revenue and Gross Margin (2021-2026)
  89. 7.15.4 Asahi Kasei Musculoskeletal System Disorder Drug Product Portfolio
  90. 7.15.5 Asahi Kasei Recent Developments
  91. 7.16 Amgen
  92. 7.16.1 Amgen Company Information
  93. 7.16.2 Amgen Business Overview
  94. 7.16.3 Amgen Musculoskeletal System Disorder Drug Revenue and Gross Margin (2021-2026)
  95. 7.16.4 Amgen Musculoskeletal System Disorder Drug Product Portfolio
  96. 7.16.5 Amgen Recent Developments
  97. 7.17 Abbott
  98. 7.17.1 Abbott Company Information
  99. 7.17.2 Abbott Business Overview
  100. 7.17.3 Abbott Musculoskeletal System Disorder Drug Revenue and Gross Margin (2021-2026)
  101. 7.17.4 Abbott Musculoskeletal System Disorder Drug Product Portfolio
  102. 7.17.5 Abbott Recent Developments
8 North America
  1. 8.1 North America Musculoskeletal System Disorder Drug Revenue (2021-2032)
  2. 8.2 North America Musculoskeletal System Disorder Drug Revenue by Type (2021-2032)
  3. 8.2.1 North America Musculoskeletal System Disorder Drug Revenue by Type (2021-2026)
  4. 8.2.2 North America Musculoskeletal System Disorder Drug Revenue by Type (2027-2032)
  5. 8.3 North America Musculoskeletal System Disorder Drug Revenue Share by Type (2021-2032)
  6. 8.4 North America Musculoskeletal System Disorder Drug Revenue by Application (2021-2032)
  7. 8.4.1 North America Musculoskeletal System Disorder Drug Revenue by Application (2021-2026)
  8. 8.4.2 North America Musculoskeletal System Disorder Drug Revenue by Application (2027-2032)
  9. 8.5 North America Musculoskeletal System Disorder Drug Revenue Share by Application (2021-2032)
  10. 8.6 North America Musculoskeletal System Disorder Drug Revenue by Country
  11. 8.6.1 North America Musculoskeletal System Disorder Drug Revenue by Country (2021 VS 2025 VS 2032)
  12. 8.6.2 North America Musculoskeletal System Disorder Drug Revenue by Country (2021-2026)
  13. 8.6.3 North America Musculoskeletal System Disorder Drug Revenue by Country (2027-2032)
  14. 8.6.4 United States
  15. 8.6.5 Canada
  16. 8.6.6 Mexico
9 Europe
  1. 9.1 Europe Musculoskeletal System Disorder Drug Revenue (2021-2032)
  2. 9.2 Europe Musculoskeletal System Disorder Drug Revenue by Type (2021-2032)
  3. 9.2.1 Europe Musculoskeletal System Disorder Drug Revenue by Type (2021-2026)
  4. 9.2.2 Europe Musculoskeletal System Disorder Drug Revenue by Type (2027-2032)
  5. 9.3 Europe Musculoskeletal System Disorder Drug Revenue Share by Type (2021-2032)
  6. 9.4 Europe Musculoskeletal System Disorder Drug Revenue by Application (2021-2032)
  7. 9.4.1 Europe Musculoskeletal System Disorder Drug Revenue by Application (2021-2026)
  8. 9.4.2 Europe Musculoskeletal System Disorder Drug Revenue by Application (2027-2032)
  9. 9.5 Europe Musculoskeletal System Disorder Drug Revenue Share by Application (2021-2032)
  10. 9.6 Europe Musculoskeletal System Disorder Drug Revenue by Country
  11. 9.6.1 Europe Musculoskeletal System Disorder Drug Revenue by Country (2021 VS 2025 VS 2032)
  12. 9.6.2 Europe Musculoskeletal System Disorder Drug Revenue by Country (2021-2026)
  13. 9.6.3 Europe Musculoskeletal System Disorder Drug Revenue by Country (2027-2032)
  14. 9.6.4 Germany
  15. 9.6.5 France
  16. 9.6.6 U.K.
  17. 9.6.7 Italy
  18. 9.6.8 Russia
  19. 9.6.9 Spain
  20. 9.6.10 Netherlands
  21. 9.6.11 Switzerland
  22. 9.6.12 Sweden
  23. 9.6.13 Poland
10 China
  1. 10.1 China Musculoskeletal System Disorder Drug Revenue (2021-2032)
  2. 10.2 China Musculoskeletal System Disorder Drug Revenue by Type (2021-2032)
  3. 10.2.1 China Musculoskeletal System Disorder Drug Revenue by Type (2021-2026)
  4. 10.2.2 China Musculoskeletal System Disorder Drug Revenue by Type (2027-2032)
  5. 10.3 China Musculoskeletal System Disorder Drug Revenue Share by Type (2021-2032)
  6. 10.4 China Musculoskeletal System Disorder Drug Revenue by Application (2021-2032)
  7. 10.4.1 China Musculoskeletal System Disorder Drug Revenue by Application (2021-2026)
  8. 10.4.2 China Musculoskeletal System Disorder Drug Revenue by Application (2027-2032)
  9. 10.5 China Musculoskeletal System Disorder Drug Revenue Share by Application (2021-2032)
11 Asia (Excluding China)
  1. 11.1 Asia Musculoskeletal System Disorder Drug Revenue (2021-2032)
  2. 11.2 Asia Musculoskeletal System Disorder Drug Revenue by Type (2021-2032)
  3. 11.2.1 Asia Musculoskeletal System Disorder Drug Revenue by Type (2021-2026)
  4. 11.2.2 Asia Musculoskeletal System Disorder Drug Revenue by Type (2027-2032)
  5. 11.3 Asia Musculoskeletal System Disorder Drug Revenue Share by Type (2021-2032)
  6. 11.4 Asia Musculoskeletal System Disorder Drug Revenue by Application (2021-2032)
  7. 11.4.1 Asia Musculoskeletal System Disorder Drug Revenue by Application (2021-2026)
  8. 11.4.2 Asia Musculoskeletal System Disorder Drug Revenue by Application (2027-2032)
  9. 11.5 Asia Musculoskeletal System Disorder Drug Revenue Share by Application (2021-2032)
  10. 11.6 Asia Musculoskeletal System Disorder Drug Revenue by Country
  11. 11.6.1 Asia Musculoskeletal System Disorder Drug Revenue by Country (2021 VS 2025 VS 2032)
  12. 11.6.2 Asia Musculoskeletal System Disorder Drug Revenue by Country (2021-2026)
  13. 11.6.3 Asia Musculoskeletal System Disorder Drug Revenue by Country (2027-2032)
  14. 11.6.4 Japan
  15. 11.6.5 South Korea
  16. 11.6.6 India
  17. 11.6.7 Australia
  18. 11.6.8 Taiwan
  19. 11.6.9 Southeast Asia
12 South America, Middle East and Africa
  1. 12.1 SAMEA Musculoskeletal System Disorder Drug Revenue (2021-2032)
  2. 12.2 SAMEA Musculoskeletal System Disorder Drug Revenue by Type (2021-2032)
  3. 12.2.1 SAMEA Musculoskeletal System Disorder Drug Revenue by Type (2021-2026)
  4. 12.2.2 SAMEA Musculoskeletal System Disorder Drug Revenue by Type (2027-2032)
  5. 12.3 SAMEA Musculoskeletal System Disorder Drug Revenue Share by Type (2021-2032)
  6. 12.4 SAMEA Musculoskeletal System Disorder Drug Revenue by Application (2021-2032)
  7. 12.4.1 SAMEA Musculoskeletal System Disorder Drug Revenue by Application (2021-2026)
  8. 12.4.2 SAMEA Musculoskeletal System Disorder Drug Revenue by Application (2027-2032)
  9. 12.5 SAMEA Musculoskeletal System Disorder Drug Revenue Share by Application (2021-2032)
  10. 12.6 SAMEA Musculoskeletal System Disorder Drug Revenue by Country
  11. 12.6.1 SAMEA Musculoskeletal System Disorder Drug Revenue by Country (2021 VS 2025 VS 2032)
  12. 12.6.2 SAMEA Musculoskeletal System Disorder Drug Revenue by Country (2021-2026)
  13. 12.6.3 SAMEA Musculoskeletal System Disorder Drug Revenue by Country (2027-2032)
  14. 12.6.4 Brazil
  15. 12.6.5 Argentina
  16. 12.6.6 Chile
  17. 12.6.7 Colombia
  18. 12.6.8 Peru
  19. 12.6.9 Saudi Arabia
  20. 12.6.10 Israel
  21. 12.6.11 UAE
  22. 12.6.12 Turkey
  23. 12.6.13 Iran
  24. 12.6.14 Egypt
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst